Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Tehran University of Medical Sciences.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Tehran University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01099059
First received: April 3, 2010
Last updated: November 17, 2010
Last verified: November 2010
  Purpose

Attention-deficit hyperactivity disorder (ADHD) is the most common neurobehavioural disorder of childhood. The investigators hypothesized that amantadine would be beneficial for treatment of ADHD, and this could be evaluated in a double blind, randomized, parallel group comparison of amantadine and ritalin.

This will be a six-week, parallel group, randomized clinical trial undertaken in an outpatient child and adolescent clinic at Roozbeh Psychiatric Hospital in Tehran, Iran during April 2010-May 2010.

50 male and female subjects, ages 6 to 17 years with a DSM-IV-TR diagnosis of ADHD will be study population of this trial. At screening, investigators conduct a psychiatric evaluation with the DSM-IV-TR criteria for ADHD and the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime diagnostic interview and perform a complete medical history and physical examination.

The diagnosis of ADHD will be confirmed by a child and adolescent psychiatrist before participants will be initiated into the study. All patients will be newly diagnosed. Parents were carefully interview and ask to rate the severity of the DSM-IV-TR ADHD symptoms that their children display at home. Children will be excluded if they have a history or current diagnosis of pervasive developmental disorders, schizophrenia or other psychiatric disorders(DSM-IV axis I); any current psychiatric comorbidity that required pharmacotherapy; any evidence of suicide risk and mental retardation (I.Q. <70). In addition, patients will be excluded if they have a clinically significant chronic medical condition, including organic brain disorder, seizures and, current abuse or dependence on drugs within 6 months. Additional exclusion criteria will be hypertension, hypotension. To participate, parents and children have to be willing to comply with all requirements of the study. After a description of the procedures and purpose of the study, written informed consent will be obtained from each patient's parent or guardian. Informed consent will receive before the administration of any study procedure or dispensing of study medication in accordance with the ethical standards of the investigative site's institutional review board and with the Helsinki declaration of 1975, as revised in 2000. The protocol will be approved by the Institutional Review Board (IRB) of Tehran University of Medical Sciences.

Patients will be randomized to receive amantadine or ritalin in a 1: 1 ratio using a computer-generated code.

All study subjects will be randomly assigned to receive treatment using amantadine 100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg) or ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg) (group 2) for a 6 week double blind, randomized clinical.

The principal measure of outcome will be the Parent and Teacher ADHD Rating Scale-IV that has been used extensively in Iran in school-age children and provides valid measures of behavioral abnormality and attention trial.

Side effects will be systematically recorded throughout the study and will be assessed using a checklist that comprises 20 side effects including psychic, neurologic, autonomic and other side effects, administered by a child psychiatrist on days 7, 21and 42.


Condition Intervention Phase
Attention Deficit Hyperactivity Disorder
Drug: Amantadine
Drug: ritalin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Amantadine VS Ritalin in the Treatment of ADHD: a Double Blind Randomized Trial

Resource links provided by NLM:


Further study details as provided by Tehran University of Medical Sciences:

Primary Outcome Measures:
  • The mean decrease in ADHD -RS-IV score from baseline will be used as the main outcome measure of response of ADHD treatment. [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
    ADHD-RS-IV is an instrument that assesses the 18 symptoms of ADHD as defined in the DSM-IV-TR according to a 4-point Likert scale.


Estimated Enrollment: 40
Study Start Date: April 2010
Estimated Study Completion Date: June 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ritalin
receive ritalin depending on weight
Drug: ritalin
ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)
Experimental: Amantadine
100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
Drug: Amantadine
Amantadine 100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 50 male and female subjects, ages 6 to 17 years with a DSM-IV-TR diagnosis of ADHD will be study population of this trial. At screening, investigators conduct a psychiatric evaluation with the DSM-IV-TR criteria for ADHD and the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime diagnostic interview and perform a complete medical history and physical examination.

Exclusion Criteria:

  • Children will be excluded if they have a history or current diagnosis of pervasive developmental disorders, schizophrenia or other psychiatric disorders(DSM-IV axis I)
  • Any current psychiatric comorbidity that required pharmacotherapy
  • Any evidence of suicide risk and mental retardation (I.Q. <70).
  • In addition, patients will be excluded if they have a clinically significant chronic medical condition, including organic brain disorder, seizures and, current abuse or dependence on drugs within 6 months.
  • Additional exclusion criteria will be hypertension, hypotension.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01099059

Contacts
Contact: Shahin Akhondzadeh, Ph.D. +98-21-88952510 s.akhond@nea.net

Locations
Iran, Islamic Republic of
Tehran University of Medical Sciences Recruiting
Tehran, Iran, Islamic Republic of, 13337
Contact: Shahin Akhondzadeh, Ph.D.    +98-21-88952510    s.akhond@neda.net   
Principal Investigator: Shahin Akhondzadeh, Ph.D.         
Sponsors and Collaborators
Tehran University of Medical Sciences
Investigators
Principal Investigator: Shahin Akhondzadeh, Ph.D. TUMS
  More Information

No publications provided

Responsible Party: Prof. Shahin Akhondzadeh, Tehran University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01099059     History of Changes
Other Study ID Numbers: 8630
Study First Received: April 3, 2010
Last Updated: November 17, 2010
Health Authority: Iran: Ministry of Health

Keywords provided by Tehran University of Medical Sciences:
Attention-deficit/hyperactivity disorder
Clinical Trial
Amantadine
Methylphenidate

Additional relevant MeSH terms:
Disease
Hyperkinesis
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Amantadine
Methylphenidate
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Stimulants
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on September 18, 2014